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Background: RUNX1/AML1, which is a Runt family transcription factor critical for normal hematopoiesis, is
frequently mutated or translocated in a broad spectrum of hematopoietic malignancies.
Findings: We describe here the case of a 54-year-old female developed acute myeloid leukemia with a t(5;21)(q21;q22).
Transcriptome sequencing identified the chromodomain-helicase-DNA-binding protein 1 gene, CHD1, as a novel partner
gene of RUNX1. Furthermore, the patient was found to harbor FLT3-ITD mutation, which might collaborated
with CHD1-RUNX1 in the development of acute myeloid leukemia.
Conclusions: We have identified CHD1 as the RUNX1 fusion partner in acute myeloid leukemia with t(5;21)(q21;q22).
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The RUNX1 (previously AML1) gene encodes a DNA
binding subunit of the core binding factor (CBF), which
is critical for normal hematopoiesis. It is reported that
RUNX1 frequently mutated or translocated with at least
61 different chromosomal loci in a broad spectrum of
hematopoietic malignancies. To date, more than 20 dis-
tinct RUNX1 gene fusions have been reported in a var-
iety of hematologic malignancies [1-4]. However, about
half of RUNX1 translocations remain uncharacterized at
the molecular level. Identification of those unknown fu-
sion partners of RUNX1 will provide more clues about
the molecular and pathogenic mechanisms of these
translocations. Recently, whole transcriptome sequen-
cing (also known as RNA-Sequencing, RNA-seq) has
been shown as an efficient tool to identify uncharacter-
ized fusion genes [5]. We describe here the identification
of a novel fusion gene involving RUNX1 by case of a 54-
year-old female developed acute myeloid leukemia with
a t(5;21)(q21;q22) by transcriptome sequencing.* Correspondence: ainingsun@hotmail.com; chensuning@sina.com
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(http://creativecommons.org/publicdomain/zeroA 54-year-old female was admitted to our hospital in
January 2011 because of fever and fatigue. Examination
of peripheral blood indicated a platelet count of 103 ×
109/L, hemoglobin level of 60 g/L, and a white blood cell
count of 9.37 × 109/L with 22% circulating blasts. Bone
marrow (BM) was hypercellular with 87.5%. Flow cytom-
etry (FCM) immunophenotyping analysis showed posi-
tivity for CD34, CD14, CD13, CD33, CD117, CD15,
CD11b and HLA-DR, as well as negativity for CD19,
CD10, CD22, CD20, CD7, CD2, CD5 and CD3. The pa-
tient’s clinical picture was consistent with a diagnosis of
AML-M4 according to the FAB classification, and AML
not otherwise specified, acute myelomonocytic leukemia
according to the World Health Organization (WHO)
classification [6]. She was treated with induction chemo-
therapy of the IA regimen, including idarubicin and
cytosine arabinoside. She achieved complete remission
(CR) and received several courses of consolidation
chemotherapy. However, her leukemia relapsed in April
2012. She was refractory to several courses of intensive
combination chemotherapy and died in April 2013.
The BM cells of this patient at presentation showed an
karyotype of 46,XX,t(5;21)(q21;q22) (Figure 1A). RT-
PCR analysis failed to detect RUNX1-RUNX1T1 fusionle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver




Figure 1 Cytogenetic and fluorescence in situ hybridization analyses of the patient. The bone marrow cells were cultured for 24 h and were analyzed
for karyotyping and fluorescence in situ hybridization (FISH) with standard procedures. Clonal karyotypic abnormalities were described according to
the International System for Human Cytogenetic Nomenclature (ISCN, 2009). A) Karyotype was analyzed on R-banded metaphases showing a
t(5;21)(q21;q22), suggesting the involvement of the RUNX1 gene located at 21q22. B) FISH analysis of the rearrangement of RUNX1 by using BAC
probes RP11-177 L11 (red) and RP11-77I17 (green).The separated red and green signals indicated a translocation involving RUNX1 gene.
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RUNX1 rearrangements, dual color fluorescence in situ
hybridization (FISH) experiments were performed with
two contiguous BAC clones: RP11-177 L11, labeled with
Spectrum Red-dUTP, and RP11-77I17, labeled with
Spectrum Green-dUTP. FISH analysis showed one yellow
signal corresponding to an intact RUNX1 gene, one sepa-
rated red signal, and one separated green signal indicating
a translocation involving RUNX1 gene (Figure 1B). Thus,
3’-rapid amplification of cDNA ends (3’RACE) and RT-
PCR were performed to investigate the fusion partner of
RUNX1 and failed to detect positive results.
For the identification of the novel fusion gene in this
patient, we performed whole-transcriptome sequencing
of blast cells. Transcriptome sequence data were gener-
ated by high-throughput RNA sequencing performed on
the Illumina HiSeq 2000. Candidate fusions were verified
by RT-PCR amplification and bi-directional Sanger se-
quencing. Bioinformatic evaluation of the transcriptional
sequencing data revealed 1 novel fusion, CHD1-RUNX1,
in the patient. RT-PCR using primers for CHD1-RUNX1
fusion transcripts detected two bands (523 bp and
384 bp) corresponding to CHD1-RUNX1 fusion tran-
scripts in this patient, while a normal individual had a
negative result (Figure 2A). Sequence analysis indicated
that the 523 bp PCR fragment was the product of a fu-
sion event between exon 26 of CHD1 and exon 6 ofRUNX1 (TypeI) (Figure 2B). In addition, we found that
the 384 bp PCR fragment was the product of a fusion
event between exon 25 of CHD1 and exon 6 of RUNX1
(TypeII) (Figure 2B). This suggested that the RUNX1
breakpoint was in intron 5 and had generated alternative
fusion splice variants. The typeII fusion transcripts
retained part of the “Runt homology domain” (RHD) as
well as the whole Runx transcription activation and in-
hibition domain (TAD and TID). However, the typeI fu-
sion led to a premature stop codon (TAG) forty-two
amino acids downstream of the junction point. This
out-of-frame fusion resulted in a truncated fusion pro-
tein presumably with nonfunctional RUNX1 domains
(Figure 2C). For the detection of the reciprocal RUNX1-
CHD1 transcript, a RUNX1 sense primer and a CHD1
antisense primer were used but no fusion transcript could
be detected.
Internal tandem duplication (ITD) mutations of the
FLT3 gene have been described in approximate 20-25%
of AML [7]. In the present case, we identified an internal
tandem mutation of the FLT3 gene (FLT3-ITD) by using
Gene Scanning as previously described [8] (Additional
file 1: Figure S1).
Most chimeric gene involving RUNX1 fuse the 5’ part
of the RUNX1 gene with the 3’ part of the partner gene.
These fusion proteins retain RHD domain of RUNX1
which is responsible for heterodimerization with the
Figure 2 Characterization of the CHD1-RUNX1 fusion. A) RT-PCR confirmation for the CHD1-RUNX1 fusion. Lane M: 100 bp ladder; Lane 1: reagent
control; Lane 2: negative control from a normal individual; Lane 3: CHD1-RUNX1 transcripts (523 bp and 384 bp) were detected in the patient discussed
here. B) Sequencing analysis revealed two variant fusion transcripts between CHD1 and RUNX1.TypeI was a fusion between exon 26 of CHD1 and exon
6 of RUNX1, Type II was a fusion between exon 25 of CHD1 and exon 6 of RUNX1.The arrows indicated the fusion junction between CHD1 and RUNX1,
the arabic numbers (1190, 1236, 169) indicated the amino acids position. C) Schematic structures of chimeric fusion proteins. The TypeII fusion protein
retained the RUNX1 inhibition domain, however, the TypeI fusion created a frameshift and stop codon in the RUNX1 region, which resulted in a
truncated protein without functional RUNX1 domain.
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loss the TAD and TID domains, such as RUNX1-
RUNXT1, RUNX1-MECOM, and RUNX1-LPXN [9].
However, there are two chimeric genes, namely ETV6-
RUNX1 and USP16-RUNX1, which fuse the 5’ region of
partner gene with 3’ region of RUNX1. ETV6-RUNX1
retains RHD, TAD and TID domains of RUNX1. How-
ever, USP16-RUNX1 does not retain the RHD and no
putative chimeric protein seems to be encoded due to
loss of the open-reading frame [10,11]. Notably, our
study identify a novel fusion gene CHD1-RUNX1, which
is generated by 5’ region of CHD1 and 3’ region of
RUNX1, retains the whole TAD and TID, and part of
RHD. The incomplete RHD is likely to impair the DNA
binding capacity of RUNX1 or its heterodimerization
with CBF-β.
CHD1 locates in 5q15 and encodes a protein composed
of 1710 amino acids. CHD1 is a chromatin-remodeling en-
zyme that belongs to the chromodomain family of proteins
that play an important role in transcriptional regulation
and developmental processes [12]. It has been reported
that CHD1 is involved in assembly, shifting and removal of
nucleosomes from the DNA double helix to keep them in
an open and transcriptionally active state [13]. Two re-
search groups have reported independently that CHD1
plays a tumor-suppressor role in prostate cancer [14,15].
However, the role of CHD1 in hematological malignancies
remains unknown. By analyzing karyotypic results of over
6000 newly-diagnosed patients with acute leukemia admit-
ted to our institute between January 1985 and February
2015, we detected t(5;21)(q21;q22) translocation in two
AML patients. One was a 47-year-old male patient who
was diagnosed with AML-M2 in April 1994. The other
one (the present case, NO. 201100834) was a 54-year-old
female diagnosed with AML-M4. We identified the
CHD1-RUNX1 fusion transcript from the female case.
Animal models have revealed that RUNX1-related trans-
locations or haploinsufficiency of RUNX1 are necessary
but not sufficient for leukemogenesis [16,17], which sug-
gests the requirement for additional genetic lesion for the
development of leukemia. Internal tandem duplications
(ITDs) in the juxtamembrane (JM) domain of FLT3 that
lead to constitutive kinase activation in AML are asso-
ciated with higher early relapse rate and inferior overall
survival in patients with normal karyotype [18-20]. Fur-
thermore, FLT3-ITD could cooperate strongly in
leukemia induction with a variety of leukemia-initiating
gene fusions such as AML1-ETO, MLL-AF9, or PML-
RAR α [17,21,22]. We found the present patient harbor-
ing the FLT3-ITD mutation which might cooperate with
CHD1-RUNX1 in the induction of AML.
Taken together, we have identified a novel CHD1-RUNX1
fusion consistent with the described t(5;21)(q21;q22)
in a female patient with de novo AML (M4). Its rolein the pathogenesis of AML still requires extensive
investigation.Additional file
Additional file 1: Figure S1. Genescan analysis of FLT3-ITDs using
automated capillary gel electrophoresis. A) WT-FLT3 (328 bp) was shown
in a normal individual. B) WT-FLT3 and FLT3-ITDs (358 bp) was shown in
the present case.
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